Premium Company Profile: Pharmion Corporation

Publication Date	November 2007
Publisher	Datamonitor
Product Type	Report
Pages	49
ISBN Number	not applicable
Product Code	DAT08683

Price

£265.00
approximately: $495 | €336

PDF

PRINT £315 ($589 | €400)

Order above formats by FAX

Summary

Pharmion's main focus is to acquire, develop and commercialize products for the treatment of hematology and oncology patients. As a part of its business strategy, Pharmion intends to acquire or in-license rights to product candidates and enter into research and development collaborations.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Pharmion is focused on the development and commercialization of products for various oncology and hematology indications. The company is uniquely positioned in the field of epigenetics, a promising area of cancer research that examines reversible changes in gene regulation.

Pharmion markets four products namely Vidaza, Thalidomide Pharmion, Innohep and Refludan. The company derives all its revenues from marketing of pharmaceutical products. The company's total revenues increased from $5 million in 2002 to $239 million in 2006. This represents an absolute total growth of +$234 million for total revenues.

Pharmion's sales are forecasted to grow at a CAGR of 24% increasing from $229 million in 2006 to $547 million in 2010. The company's biggest contributor to sales growth out to 2010 will be the sales of Satraplatin which is expected to launch in 2008.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Table Of Contents
- Overview
- Catalyst
- Summary
- Company Structure
- Company Overview And Key Facts
- Business Description
- History
- Locations And Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Geographic Segment Performance
- Products & Services
- Marketed Products
- Pipeline Products
- Historical Product Sales
- Ac Forecast Product Sales
- Competitors And Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- Swot Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery And Product Development
- Sales
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
List Of Key Employees
- Key Employee Biographies
- Financial And Operational Overview
- Financial And Operational Overview
Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
Table Of Figures
- Figure 1: Pharmion - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Pharmion - Key Strategic Revenues, 2002-2006 ($ Mn)
- Figure 3: Pharmion - Key Strategic Revenues, 2006-2010 ($ Mn)
Table Of Tables
- Table 1: Pharmion - Key Facts
- Table 2: Pharmion - Locations And Subsidiaries
- Table 3: Pharmion - Year-End Share Price And Market Capitalization, 2002-2006 ($)
- Table 4: Pharmion - Key Events Impacting Share Price Performance
- Table 5: Pharmion - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Pharmion - Operating Cost Ratio Analysis, 2002-2006 (% Of Total Revenues)
- Table 7: Pharmion - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Pharmion - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Pharmion - Geographic Breakdown, 2002-2006 ($ Mn)
- Table 10: Pharmion - Marketed Products
- Table 11: Pharmion - In-House Pipeline Products
- Table 12: Pharmion - Collaboration Pipeline Products
- Table 13: Pharmion - Historical Product Sales, 2002-2006 ($ Mn)
- Table 14: Pharmion - Forecast Sales, 2006-2010 ($ Mn)
- Table 15: Pharmion -Key Competitors
- Table 16: Pharmion -Key Suppliers
- Table 17: Pharmion -Key Clients
- Table 18: Pharmion - Key Shareholders
- Table 19: Pharmion - Swot Analysis Summary
- Table 20: Pharmion - Value Chain Analysis
- Table 21: Pharmion - Scorecard
- Table 22: Pharmion - Key Employees
- Table 23: Pharmion - Financial And Operational Overview